Business
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without
About this update from Orchestra Biomed Holdings, Inc.
[{"type":"text","content":"New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon deliveryAVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT) NEW HOPE, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies (“CRT”) 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic (“PK”) data on Virtue® Sirolimus AngioInfusion Balloon (“SAB”), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic. Virtue SAB Oral Presentation, presented by Dean Kereiakes, M.D., President and Medical Director of The Christ Hospital Heart and Vascular Institute and Professor of Clinical Medicine at The Ohio State University Dr. Kereiakes’ presentation, focused on the role of drug-coated and drug-eluting balloon angioplasty systems for the treatment of coronary in-stent restenosis (“ISR”), outlined key points of differentiation and potential advantages for Virtue SAB, including: No surface drug coating and, therefore, no drug loss in-transit to a target arterial lesion or creation of large particulates durin...